Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Search
Search results
Webinar: Ask the Expert: Dr Roly Megaw
This time we are joined by Roly Megaw, Clinical Lecturer and Honorary Consultant Ophthalmologist at University of Edinburgh and NHS Lothian
Webinar: Ask the expert with Professor Marcela Votruba
The latest webinar from Retina UK.
Renewed Momentum for XLRP: MeiraGTx Targets Rapid Approval Path for bota-vec following reacquisition from Johnson and Johnson
It has recently been announced that Meira-GTx, who originally developed bota-vec and collaborated with J&J during its early clinical trials, have entered into an asset purchase agreement with J&J to acquire bota-vec and progress the program towards global regulatory filings for approval.
Genetics and gene therapy
When we talk about gene therapy we are usually referring to use of a harmless virus, called a vector, to deliver a normal copy of a defective gene into the cells of the eye.
Study of substances in blood suggests choroideremia is not just an isolated eye disease
Choroideremia is a rare genetic condition resulting in progressive sight loss in men.
e-Newsletter April 2026
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Information and support
Are you affected by inherited sight loss? We are here to help.
Birthday Fundraising
Mark your special day, whilst fundraising for people with inherited sight loss.